SUBLOCADETM (buprenorphine extended-release) Injection for Subcutaneous Use (CIII)
SUBLOCADE was approved by the FDA in the U.S. on November 30, 2017
View press release here
View full U.S. Prescribing Information, including BOXED Warning here
Along with Indivior’s robust pipeline of lifecycle products and innovative product development, our investors are what help make our vision such a demonstrable success. View important investor information here.